Mezzion Pharma的价格 / 远期销售额是1.9x. 查看Mezzion Pharma Co Ltd的价格 / 远期销售额趋势、图表等
Mezzion Pharma的ev/远期ebitda减资本支出是6.7x. 查看Mezzion Pharma Co Ltd的EV/远期EBITDA减资本支出趋势、图表等
Mezzion Pharma Co. Ltd., announced that it has re-submitted a New Drug Application to the U.S. Food and Drug Administration for the approval of udenafil to improve the exercise capacity of patients 12 ...